Federated Hermes
VRNA

Federated Hermes’s Verona Pharma VRNA Stock Holding History

Federated Hermes’s Portfolio VRNA Stock Details VRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,146,095
Closed -$108M – 2243
2025
Q2 		$108M Sell
1,146,095
-121,666
-10% -$9.01M 0.2% 132
2025
Q1 		$80.5M Sell
1,267,761
-557,532
-31% -$33.3M 0.17% 149
2024
Q4 		$84.8M Sell
1,825,293
-342,607
-16% -$12.9M 0.19% 145
2024
Q3 		$62.4M Buy
2,167,900
+4,300
+0.2% +$106K 0.14% 196
2024
Q2 		$31.3M Sell
2,163,600
-95,000
-4% -$1.39M 0.07% 303
2024
Q1 		$36.3M Sell
2,258,600
-234,930
-9% -$4.06M 0.08% 280
2023
Q4 		$49.6M Hold
2,493,530
– – 0.12% 213
2023
Q3 		$40.6M Buy
2,493,530
+822,832
+49% +$15.8M 0.11% 228
2023
Q2 		$35.3M Buy
1,670,698
+1,268,648
+316% +$27.1M 0.09% 269
2023
Q1 		$8.07M Buy
+402,050
New +$8.68M 0.02% 596

Other funds holding VRNA

PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Federated Hermes's VRNA Position: Q3 2025 in Review

Federated Hermes sold out of Verona Pharma (VRNA) in Q3 2025, closing a stake of 1,146,095 shares — an estimated $108M sold.

Federated Hermes first reported a position in VRNA in Q1 2023 and held it in 10 quarters. The position peaked at $108M in Q2 2025. 243 funds tracked by Wall St. Rank hold VRNA as of Q3 2025.

  • Federated Hermes reported no remaining Verona Pharma position as of Q3 2025 after selling out during the quarter.
  • Federated Hermes sold 1,146,095 Verona Pharma shares in Q3 2025, an estimated $108M.
  • Federated Hermes first reported a position in Verona Pharma in Q1 2023 and held it in 10 quarters.
  • Federated Hermes's Verona Pharma position peaked at $108M in Q2 2025.
  • 243 funds tracked by Wall St. Rank held Verona Pharma as of Q3 2025.

Based on Federated Hermes's 13F filing for Q3 2025, filed 3 Nov 2025.